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etter to the Editor
o follow  or  not to  follow  the recommendations
egarding microscopic  analysis  of  the Clinical  and
aboratory Standards  Institute  H20-A2  to validate
iehe criteria  for  blood  smear  rev
ear Editor,
e  read with great interest the Letter to the Editor by Grotto1
n the need to follow the Clinical and Laboratory Standards
nstitute 2007 H20-A22 guidelines during microscopic analy-
is in reply to the study by Comar et al.3 We  appreciate the
omments that ensured extensive discussion on this subject.
The work of Barnes et al.,4 which represents the core of
he criteria for blood smear review (BSR) recommended by
he International Society for Laboratory Hematology (ISLH),
manates from an international consensus among 20 experts
n 2002 during a conference in Indian Wells, CA, USA. In
onsensus, Barnes et al.4 proposed a nine-step protocol for
alidating the BSR criteria in routine laboratory practices. Step
 of this protocol is as follows: “Perform a slide review of all
amples. Limit the reviews to only one or two senior tech-
ologists for consistency. Manual differentials should only be
erformed if there is a speciﬁc need to do so (e.g., Vote out,
bnormal cell-type ﬂags, etc.)”
The step-wise protocol by Barnes et al.4 does not mention
he NCCLS H20-A5 as a sine qua non condition for the micro-
copic review of blood smears. In their work, Barnes et al.4 did
ot mandate the application of the NCCLS H20-A5 guidelines,
s interpreted by Grotto.1 Thus, Barnes et al.4 did not exclude
he possibility of one observer counting 100 cells to validate
he BSR criteria. We therefore understand that counting per-
ormed by either one or two observers is equally acceptable.
The CLSI H20-A22 (formerly NCCLS H20-A)5 is a reference
ocument to evaluate hematology analyzers that perform
utomated leukocyte differential counts and consider the
isual leukocyte differential count as the gold standard. Most
tudies that rigorously followed this guideline speciﬁcally
valuated the automated leukocyte differential count and the
uspect ﬂags of the hematology analyzers.6,7 On the other
and, studies evaluating sets of criteria for BSR did not nec-
ssarily follow the recommendations of the NCCLS H20-A5 orw?
CLSI H20-A22 regarding the microscopic analysis.4,8–11 Thus,
we emphasize that, in the study of Comar et al.3 the step-wise
rules of Barnes et al.4 that exclusively deal with the validation
of the BSR criteria were followed.
We believe that Barnes et al.4 recommended slide review by
either one or two observers, without specifying a set number
of slides per sample nor the number of cells to be counted per
slide, to enable application of the same protocols of sample
collection and processing as in routine protocols for valida-
tion purpose, thus simulating the real-time conditions of most
hematology laboratories.
We  evaluated the criteria for BSR by using the hematology
analyzers provided by Sysmex Corporation.3 The application
of the criteria for BSR adapted from ISLH resulted in high
false negative (FN) (>5%) and microscopic review rates (MRR).
Similar results were reported by Xing et al.12 in an analysis
of 2400 samples using the ADVIA 120/2120 hematology ana-
lyzer, according to the screening criteria proposed by ISLH and
their own positive smear ﬁndings [FN = 5.5%, false positives
(FP) = 28.1%, and MRR = 50.2%]. It is important to emphasize
that we  did not conclude “the inadequate performance of
both pieces of equipment” in any instance of the proposals
by Comar et al.3 We explained that 30% of the FP results (i.e.,
6.98% of the total samples or 138 samples in 1977) occurred
due to the presence of suspect ﬂags in the samples. This per-
centage represents the sum of all suspect ﬂags generated in
all samples and whose microscopic counterpart did not pro-
vide any positive smear ﬁnding. We believe that the FP rates
observed by Comar et al.3 can be partially attributed to the
proﬁle of the samples analyzed and not to the brand or type
of hematology analyzer used. As evidence, in another labo-
ratory where one of the authors works and which generally
attends outpatients, the application of the same criteria for
BSR using similar hematology analyzers resulted in a daily
MRR  of 5–20%, an FP rate of 3–10%, and an FN rate of <5%
(unpublished data).
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In our experience, in individual analysis, the main suspect
ﬂags delivered the following results using the XE-2100D hema-
tology analyzer for samples similar to those used by Comar
et al.3: The FN rate and efﬁciency for immature granulocytes
were 1.15% and 94.71%; the FN rate for blasts was 0.17% (n = 3
samples); and the efﬁciency, sensitivity, and speciﬁcity for Left
Shift were 82.4%, 44%, and 92.08%, respectively.13 Therefore,
unlike Grotto’s (1) interpretation, the performances of these
suspect ﬂags were almost similar to those reported by Stam-
minger et al.6 and Ruzicka et al.14
In summary, each laboratory should establish its own cri-
teria for BSR of blood counts according to their peculiarities,
possibilities, and limitations, and it should follow the appro-
priate guidelines and tools to validate such criteria in routine
laboratory practices. After a careful analysis of the results dis-
cussed above, we  conclude that the use of the rules proposed
by Barnes et al.4 was adequate in the study of Comar et al.3
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